Wesbanco Bank Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 338,055 shares of the biopharmaceutical company’s stock after selling 992 shares during the period. Wesbanco Bank Inc.’s holdings in Pfizer were worth $14,756,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of PFE. Bailard Inc. lifted its holdings in Pfizer by 20.2% in the fourth quarter. Bailard Inc. now owns 31,898 shares of the biopharmaceutical company’s stock valued at $1,392,000 after acquiring an additional 5,352 shares during the period. SNS Financial Group LLC lifted its holdings in Pfizer by 2.7% in the fourth quarter. SNS Financial Group LLC now owns 112,945 shares of the biopharmaceutical company’s stock valued at $4,930,000 after acquiring an additional 2,968 shares during the period. Transamerica Financial Advisors Inc. lifted its holdings in Pfizer by 55.3% in the fourth quarter. Transamerica Financial Advisors Inc. now owns 2,563 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 913 shares during the period. Wealth Enhancement Advisory Services LLC acquired a new stake in Pfizer in the fourth quarter valued at $4,350,000. Finally, Roman Butler Fullerton & Co. acquired a new stake in Pfizer in the fourth quarter valued at $1,993,000. 67.17% of the stock is owned by hedge funds and other institutional investors.

Pfizer stock traded down $0.38 during midday trading on Friday, reaching $41.52. 21,479,398 shares of the company were exchanged, compared to its average volume of 23,199,798. The stock has a market cap of $249.43 billion, a PE ratio of 13.84, a P/E/G ratio of 2.42 and a beta of 0.71. Pfizer Inc. has a 1 year low of $35.32 and a 1 year high of $46.47. The company has a current ratio of 1.54, a quick ratio of 1.27 and a debt-to-equity ratio of 0.60.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, April 30th. The biopharmaceutical company reported $0.85 EPS for the quarter, topping analysts’ consensus estimates of $0.75 by $0.10. The firm had revenue of $13.12 billion during the quarter, compared to analysts’ expectations of $13.01 billion. Pfizer had a return on equity of 27.48% and a net margin of 21.31%. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.89 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 10th will be given a dividend of $0.36 per share. This represents a $1.44 dividend on an annualized basis and a yield of 3.47%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently 48.00%.

A number of research firms have commented on PFE. Zacks Investment Research raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, April 10th. Goldman Sachs Group initiated coverage on Pfizer in a research report on Tuesday, May 28th. They issued a “conviction-buy” rating for the company. Barclays restated a “hold” rating and issued a $41.00 price target on shares of Pfizer in a research report on Thursday, May 9th. JPMorgan Chase & Co. set a $46.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Tuesday, April 30th. Finally, Credit Suisse Group restated a “buy” rating and issued a $48.00 price target on shares of Pfizer in a research report on Monday, May 6th. Thirteen research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $45.83.

In other Pfizer news, insider Mikael Dolsten sold 149,553 shares of Pfizer stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $43.55, for a total value of $6,513,033.15. Following the completion of the sale, the insider now owns 390,097 shares in the company, valued at approximately $16,988,724.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Dawn Rogers sold 15,002 shares of Pfizer stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $42.98, for a total value of $644,785.96. Following the completion of the sale, the executive vice president now owns 28,722 shares of the company’s stock, valued at approximately $1,234,471.56. The disclosure for this sale can be found here. In the last quarter, insiders have sold 188,255 shares of company stock valued at $8,158,100. 0.09% of the stock is currently owned by company insiders.

WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://www.watchlistnews.com/wesbanco-bank-inc-sells-992-shares-of-pfizer-inc-pfe/3029411.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.